SCHEMBL16097345

SCHEMBL16097345

O=Cc1ccc(OCc2ccccc2)c(CC(F)(F)F)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.47
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCND1 P24385 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16095408 0.83 ERN1 (0.50) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL20607869 0.82 ERN1 (0.54) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL12035865 0.82 ERN1 (0.47) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL10959657 0.81 ERN1 (0.48) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL17311332 0.80 MAPT (0.41) ERN1MAPTSMN1; SMN2L3MBTL1NPC1
SCHEMBL768225 0.77 MAPT (0.66) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL16097104 0.76 ERN1 (0.51) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL986050 0.75 CCNB2 (0.62) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL31683746 0.75 CCNB2 (0.62) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9
SCHEMBL24379165 0.74 CCNB2 (0.50) ERN1MAPTSMN1; SMN2L3MBTL1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970339-B1 1-HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS LILLY CO ELI (US) 2017-08-16 EP disclosed
US-9617285-B2 1-hydroxy-benzooxaboroles as antiparasitic agents ELI LILLY AND COMPANY (US) 2017-04-11 US disclosed
EP-2970339-A1 1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS Eli Lilly and Company (US) 2016-01-20 EP disclosed
US-20150353581-A1 1-HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS ELI LILLY AND COMPANY (US) 2015-12-10 US disclosed
WO-2014149793-A1 1 -HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS ELI LILLY AND COMPANY (US) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353581-A1 1-HYDROXY-BENZOOXABOROLES AS ANTIPARASITIC AGENTS HAO1, CYP8B1, KMO ERN1 3051/4885MAPT 3959/4885SMN1; SMN2 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.